2022
Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC
Bloch EM, Day JR, Krause PJ, Kjemtrup A, O’Brien S, Tobian AAR, Goel R. Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 354-362. PMID: 35076004, PMCID: PMC8798708, DOI: 10.3201/eid2802.210213.Peer-Reviewed Original ResearchConceptsNational Inpatient Sample databaseInfectious Diseases journal - CDCAnalysis of hospitalizationsHospitalized patientsAdvanced ageMortality rateHospitalizationSample databaseObservation periodEpidemiologyHigher severityPatientsBabesiosisDiagnosisUnited StatesReporting dataBabesiaAdmissionIllnessIncidenceDiseaseSeverity
2016
Transfusion-transmitted babesiosis
Levin AE, Krause PJ. Transfusion-transmitted babesiosis. Current Opinion In Hematology 2016, 23: 573-580. PMID: 27537475, PMCID: PMC5241272, DOI: 10.1097/moh.0000000000000287.Peer-Reviewed Original ResearchConceptsTransfusion-transmitted babesiosisBlood donorsB. microti antibodiesInfectious blood donorsAssociated mortality rateOptimal screening strategyTransfusion-transmitted pathogensSignificant health burdenAvailable screening toolsUnited States populationPathogen inactivation methodsMicroti antibodiesSevere illnessHealth burdenMortality rateUS FoodDrug AdministrationBabesia microtiScreening toolLaboratory screeningScreening strategyBabesiosisInactivation methodPCR assaysRecent studies
2015
Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?
Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? Journal Of Clinical Apheresis 2015, 31: 454-458. PMID: 26481763, DOI: 10.1002/jca.21429.Peer-Reviewed Original ResearchConceptsExchange transfusionHigh-risk populationLife-threatening illnessApparent therapeutic benefitBlood transfusionModerate diseaseClinical presentationAsymptomatic infectionSevere babesiosisSevere diseaseRisk populationsTherapeutic benefitTransfusionMortality rateIntraerythrocytic protozoan parasiteBabesia infectionDiseaseIxodes ticksProtozoan parasiteBabesiosisInfectionGenus BabesiaMost casesPatientsClindamycin